european medicines agency glp-1 vision loss recommendation november 2025 Ozempic Lawsuit: July 2026 Blindness and Gastroparesis Claims European regulators want to know

Its not often that diabetes treatments make it into the monologue for the Academy Awards, but on Sunday March 12, thats exactly what happened

PlexusDx offers personalized protocols to optimize results

Carmot Therapeutics has revealed preliminary data from the single ascending dose (SAD) portion of its ongoing Phase 1 clinical trial for CT-996, an oral small molecule GLP-1 receptor agonist (RA) currently being evaluated in a first-in-human clinical trial in participants with obesity or overweight.CT-996 is a once-daily oral, small molecule GLP-1 receptor agonist being developed for the treatment of obesity and type 2 diabetes (T2D)

PlexusDx explains how to recognize when your injection has exceeded its shelf life and why fresh medication ensures optimal weight loss outcomes

In addition, each container of these GLP-1 supplements includes 60 capsules, providing a 30-day supply

The answer depends on your individual metabolism, lifestyle changes, and weight regain risk